Are all pMDI fluticasone propionate + salmeterol products the same? Preliminary report Preliminary report

Article Sidebar

PDF (Język Polski)


Published: Aug 30, 2021
DOI: https://doi.org/10.24292/01.AP.173302821
Keywords:
pressurized metered dose inhaler, fluticasone propionate, salmeterol, aerosol cloud, lung deposition, asthma, adults

Main Article Content

Tomasz R. Sosnowski
Katedra Inżynierii Procesów Zintegrowanych, Wydział Inżynierii Chemicznej i Procesowej, Politechnika Warszawska
http://orcid.org/0000-0002-6775-3766
Andrzej Emeryk
Klinika Chorób Płuc i Reumatologii Dziecięcej, Uniwersytet Medyczny w Lublinie
http://orcid.org/0000-0003-1853-8696
Kamil Janeczek
Klinika Chorób Płuc i Reumatologii Dziecięcej, Uniwersytet Medyczny w Lublinie
http://orcid.org/0000-0002-8163-873X
Justyna Emeryk-Maksymiuk
Katedra i Zakład Pielęgniarstwa Internistycznego, Uniwersytet Medyczny w Lublinie
http://orcid.org/0000-0003-2709-0424

Abstract

The paper presents the results of a study evaluating the basic parameters characterizing the aerosol cloud (aerodynamic diameter value which corresponding to the median of the mass particle size distribution, fine particle fraction, geometric standard deviation) generated by pressurized metered dose inhaler containing a combination of a glucocorticosteroid with a long-acting β2-mimetic. Three fluticasone propionate products available on the Polish market were compared with salmeterol (one reference and two generic). Based on the determined parameters, the inhaled aerosol deposition on particular levels of the respiratory system was determined. There were slight differences between the tested products.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sosnowski , T. R., Emeryk , A., Janeczek , K., & Emeryk-Maksymiuk , J. (2021). Are all pMDI fluticasone propionate + salmeterol products the same? Preliminary report. Alergoprofil, 17(3), 39-44. https://doi.org/10.24292/01.AP.173302821
Issue
Vol 17 No 3 (2021)
Section
THERAPY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Update 2021.
2. Cloutier MM, Baptist AP, Blake KV et al; Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC). 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020; 146(6): 1217-70.
3. https://pubmed.ncbi.nlm.nih.gov/?term=fluticasone+ propionate+salmeterol+combination&sort=date (access: 1.08.2021).
4. Mehta R, Daley-Yates PT, Jenkins K et al. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler. Pulm Pharmacol Ther. 2014; 29(1): 66-73.
5. Paik J, Scott LJ, Pleasants RA. Fluticasone Propionate/ Salmeterol MDPI (AirDuo RespiClick®): A Review in Asthma. Clin Drug Investig. 2018; 38(5): 463-73.
6. Kupczyk M, Majak P, Kuna P et al. A new formulation of fluticasone propionate/ salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control – A randomized, multi-center, non-inferiority, phase IV clinical study. Respir Med. 2021; 176: 106274.
7. Duexon (flutykazon (propionian flutykazonu) + salmeterol) - aerozol inhalacyjny, zawiesina (access: 2.08.2021).
8. Tashkin DP, Koltun A, Wallace R. A generic fluticasone propionate and salmeterol dry powder inhaler: Evidence of usability, function, and robustness. Allergy Asthma Proc. 2021; 42(1): 30-5
9. Emeryk A, Janeczek K, Sosnowski TR et al. Połączenia glikokortykosteroidu z długo działającym β2-mimetykiem w inhalatorze ciśnieniowy dozującym – jakie, komu, kiedy? Alergoprofil. 2021; 3: 19-26. https://doi.org/10.24292/01.AP.173300821.
10. Mao L, Wilcox D, Kippax P. Laser diffraction particle size analysis: a powerful tool for rapidly screening nebulizer formulations. Drug Delivery Techn. 2010; 10: 64-7.
11. Haynes A, Shaik MS, Krarup H et al. Evaluation of the Malvern Spraytec with inhalation cell for the measurement of particle size distribution from metered dose inhalers. J Pharm Sci. 2004; 93(2): 349-63.
12. Applied Research Associates, Inc. 2021 (access: 2.08.2021).
13. Miller FJ, Asgharian B, Schroeter JD et al. Improvements and additions to the Multiple Path Particle Dosimetry model. J Aerosol Sci. 2016; 99: 14-26.
14. Yeh HC, Schum GM. Models of human lung airways and their application to inhaled particle deposition. Bull Math Biol. 1980; 42(3): 4 61-80.
15. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. EMA, Doc. Ref. CPMP/EWP/4151/00 Rev. 1, London 2009 (access: 2.08.2021).
16. Draft Guidance on Fluticasone Propionate; Salmeterol Xinafoate. Recommended May 2019 (access: 3.08.2021).
17. Pirożynski M, Sosnowski TR. Inhalation devices: from basic science to practical use, innovative vs generic products. Expert Opin Drug Deliv. 2016; 13(11): 155 9-71.